Search results for "PEDIATRIA"

showing 10 items of 692 documents

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

2014

The outcome of high-risk (HR) Acute Lymphoblastic Leukemia (ALL) patients enrolled in AIEOP-BFM ALL 2000 study (NCT00613457) in Italy is described. Overall, 1999 Philadelphia negative ALL patients entered the study. HR criteria were: minimal residual disease (MRD) levels ≥10-3 at day 78 (HR-MRD), no complete remission (no-CR) at day 33, t(4;11) translocation, Prednisone Poor Response (PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, maintenance. 312 HR patients (15.6% of the total) had 5-year event-free survival (EFS) and overall survival (OS) of 58.9%(SE 2.8) and 68.9%(2.6). In hierarchical ord…

Malemedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentImmunologyChromosomal translocationhigh riskacute lymphoblastic leukemiaHematopoietic stem cell transplantationBiochemistryGastroenterologyAdolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neoplasm Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Remission Induction; Treatment Outcome; Hematology; Biochemistry; Cell Biology; ImmunologyPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy Protocolshigh risk; acute lymphoblastic leukemiaHumansMedicineNeoplasmPreschoolChildChemotherapyAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInfantCell BiologyHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapyMinimal residual diseaseSurgeryClinical trialRadiation therapyTreatment OutcomeN/ASettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAResidualChild PreschoolNeoplasmFemalebusinessHumanmedicine.drugBlood
researchProduct

Ischemic hypoxic encephalopathy: The role of MRI of neonatal injury and medico-legal implication

2021

Hypoxic ischemic encephalopathy is one of the major causes of neonatal death and neurological disability in the child, and represents the most common birth injury claim. Intrapartum asphyxia often leads to several long-term sequalae, such as cerebral palsy and/or developmental delay, epilepsy. Through the neuroimaging it's possible to identify and define the different lesioned pictures and provide useful elements to establish the moment in which the damage occurred; indeed, timing of injury is a key element in the legal arena. Magnetic resonance imaging (MRI) is emerging as one of the most important tools in identifying the etiologic of neonatal encephalopathy as well as in predicting long-…

Malemedicine.medical_specialtyNeuroimagingHypoxic Ischemic EncephalopathyPathology and Forensic MedicineCerebral palsyMedico-legalEpilepsySettore MED/38 - Pediatria Generale E SpecialisticaNeuroimagingSettore MED/43 - Medicina LegaleMalpractice litigationMalpracticemedicineHumansIschemic Hypoxic encephalopathyIntensive care medicineAsphyxia Neonatorummedicine.diagnostic_testNeonatal encephalopathybusiness.industryInfant NewbornInfantMagnetic resonance imagingForensic Medicinemedicine.diseaseMagnetic Resonance ImagingBirth injurySettore MED/39 - Neuropsichiatria InfantileItalyMRI brainHypoxia-Ischemia BrainCerebral palsyFemalebusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaLawHuman
researchProduct

Urinary (1)H-NMR and GC-MS metabolomics predicts early and late onset neonatal sepsis.

2014

The purpose of this article is to study one of the most significant causes of neonatal morbidity and mortality: neonatal sepsis. This pathology is due to a bacterial or fungal infection acquired during the perinatal period. Neonatal sepsis has been categorized into two groups: early onset if it occurs within 3-6 days and late onset after 4-7 days. Due to the not-specific clinical signs, along with the inaccuracy of available biomarkers, the diagnosis is still a major challenge. In this regard, the use of a combined approach based on both nuclear magnetic resonance (H-1-NMR) and gas-chromatography-mass spectrometry (GC-MS) techniques, coupled with a multivariate statistical analysis, may hel…

Malemedicine.medical_specialtyPathologyMagnetic Resonance SpectroscopySepsiUrinary systemLate onsetMetabolomicDiseaseMass SpectrometrySepsisSettore MED/38 - Pediatria Generale E SpecialisticaInternal medicineSepsismedicineMetabolomeHumansNeonatal sepsisbusiness.industryCase-control studyInfant NewbornObstetrics and Gynecologymedicine.diseaseNewbornPrognosisCase-Control StudiesPediatrics Perinatology and Child HealthMetabolomePopulation studyFemalebusinessNeonatal infectionBiomarkersEarly human development
researchProduct

A premature infant with Costello syndrome due to a rare G13C HRAS mutation.

2009

Costello syndrome is caused by mutations in the HRAS proto-oncogene whose clinical features in the first year of life include fetal and neonatal macrosomia with subsequent growth impairment due to severe feeding difficulties. We report on a premature male with Costello syndrome due to a rare G13C HRAS mutation and describe his clinical features and evolution during the first year of life. The diagnosis of Costello syndrome may be difficult at birth, especially in very preterm infants in whom feeding difficulties, reduced subcutaneous adipose tissue and failure to thrive are also part of their typical presentation.

Malemedicine.medical_specialtyPediatricsDevelopmental DisabilitiesProto-Oncogene MasprematureSettore MED/38 - Pediatria Generale E SpecialisticaCostello syndromePregnancyInternal medicineIntellectual DisabilityGeneticsmedicineHumansHRASGenetics (clinical)FetusPregnancybusiness.industryInfant NewbornNucleic acid amplification techniqueDNASyndromemedicine.diseaseEndocrinologyGenes rasSettore MED/03 - Genetica MedicaFailure to thriveMutation (genetic algorithm)MutationFemalePresentation (obstetrics)medicine.symptombusinessNucleic Acid Amplification TechniquesInfant PrematureAmerican journal of medical genetics. Part A
researchProduct

The Hikikomori Phenomenon of Social Withdrawal: An Emerging Condition Involving Youth's Mental Health and Social Participation.

2020

The objective of this editorial is to raise awareness on the burden and risks faced by adolescents developing this emerging form of social withdrawal. The hikikomori phenomenon is part of the group of new morbidities causing children and adolescents to limit their activity owing to a chronic health condition with attendant psychological problems. We further emphasize the importance of including new morbidities involving mental health and social participation in formal pediatric training, to enable new generations of pediatricians to identify and properly manage these disorders.

Malemedicine.medical_specialtySocial psychology (sociology)Adolescentmedia_common.quotation_subjectMEDLINEhikikomori phenomenonShameSocial epidemiologyShameGlobal HealthYoung AdultSettore MED/38 - Pediatria Generale E SpecialisticamedicineGlobal healthHumansPsychiatrymedia_commonbusiness.industryPhobia SocialSocial engagementmedicine.diseaseMental healthHikikomoriSocial IsolationPediatrics Perinatology and Child HealthFemalebusinessHikikomori Phenomenon Social Withdrawal Youth Mental HealthThe Journal of pediatrics
researchProduct

Fibrosarcoma in pediatric patients: Results of the Italian Cooperative Group Studies (1979-1995)

2001

Background and Objectives Fibrosarcoma is a rare soft tissue sarcoma (STS) that has two peaks of incidence in pediatric patients: one in infants and young childern (infantile fibrosarcoma), another in older children (“adult type” fibrosarcoma). The purpose of this study was to describe the clinical features and the treatment results in patients affected by fibrosarcoma enrolled in two consecutive studies run by the STS-Italian Cooperative Group (ICG) between 1979 and 1995. Patients and Methods Twenty-five evaluable patients were grouped according the intergroup rhabdomyosarcoma staging (IRS) system: 12 Gr I, 5 Gr II, 8 Gr III. The cut-off point between the two forms was considered the age o…

Malemedicine.medical_specialtyinfantile fibrosarcomaAdolescentmedicine.medical_treatmentSoft Tissue NeoplasmsSettore MED/38 - Pediatria Generale E SpecialisticamedicineHumansFibrosarcomaRhabdomyosarcomaChildSurvival analysisfibrosarcoma; infantile fibrosarcoma; soft tissue sarcomabusiness.industrySoft tissue sarcomaSettore MED/20 - Chirurgia Pediatrica E InfantileAge FactorsInfantRadiotherapy DosageSarcomaGeneral Medicinemedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryRadiation therapyTreatment OutcomeOncologyChild Preschoolsoft tissue sarcomaSurgeryFemalefibrosarcomaSarcomaInfantile FibrosarcomabusinessProgressive disease
researchProduct

14q13.1-21.1 deletion encompassing the HPE8 locus in an adolescent with intellectual disability and bilateral microphthalmia, but without holoprosenc…

2011

Interstitial deletions involving 14q13.1q21.1 are rare. In the literature at least 10 cases involving this region have been described and all patients showed a phenotype within the holoprosencephaly (HPE) spectrum. Previous studies suggested the HPE8 region as a candidate locus for HPE at 14q13. We report an adolescent with a 14q13.1q21.1 deletion encompassing the HPE8 region associated with intellectual disability (ID), bilateral microphthalmia, and coloboma, without cerebral anomalies typical of HPE. Except for ocular defects (i.e., microphthalmia, coloboma) consistent with HPE-type anomalies, the minor facial dysmorphia was not suggestive for HPE and the absence of cerebral anomalies sho…

Malemusculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesCandidate geneAdolescentID/MCA deletion syndromeLocus (genetics)MicrophthalmiamicroformSettore MED/38 - Pediatria Generale E SpecialisticaHoloprosencephalyIntellectual DisabilityIntellectual disabilityGeneticsmedicineHumansMicrophthalmoschromosome 14q deletionIn Situ Hybridization FluorescenceGenetics (clinical)Sequence DeletionChromosomes Human Pair 14GeneticsComparative Genomic HybridizationColobomabiologybusiness.industryNPAS3Faciesmedicine.diseaseeye diseasesDevelopmental disorderPhenotypeholoprosencephalySettore MED/03 - Genetica MedicaGenetic Lociarray-CGHbiology.proteinbusinessAmerican Journal of Medical Genetics Part A
researchProduct

Q289P mutation in the FGFR2 gene: first report in a patient with type 1 Pfeiffer syndrome.

2008

When normal development and growth of the calvarial sutures is disrupted, craniosynostosis (premature calvarial suture fusion) may result. Classical craniosynostosis syndromes are autosomal dominant traits and include Apert, Pfeiffer, Crouzon, Jackson-Weiss, and Saethre-Chotzen syndromes. In these conditions, there is premature fusion of skull bones leading to an abnormal head shape, ocular hypertelorism with proptosis, and midface hypoplasia. It is known that mutations in the fibroblast growth factor receptors 1, 2, and 3 cause craniosynostosis. We report on a child with a clinically diagnosed Pfeiffer syndrome that shows the missense point mutation Q289P in exon 8 of the FGFR2 gene. This …

Malemusculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyCraniosynostosisSettore MED/38 - Pediatria Generale E SpecialisticaHumansPoint MutationMedicineMissense mutationReceptor Fibroblast Growth Factor Type 2HypertelorismGeneticsFibrous jointbusiness.industryFibroblast growth factor receptor 2Craniofacial DysostosisInfantDysostosisExonsAcrocephalosyndactyliamedicine.diseaseSkullPhenotypemedicine.anatomical_structurePfeiffer - Crouzon - Apert - Craniosynostosis - Finger and toes abnormalities - Fibroblast growth factor receptorPediatrics Perinatology and Child HealthPfeiffer syndromeFemalemedicine.symptombusiness
researchProduct

Teratoma with a malignant somatic component in pediatric patients: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience

2010

BACKGROUND: Teratoma with a malignant somatic component (TMSC) is rare but described in adults, whereas information on pediatric presentation is sparse. PROCEDURE: The Associazione Italiana Ematologia Oncologia Pediatrica identified 14 cases of TMSC. Clinical files and pathology specimens were reviewed. RESULTS: The series (9 female, 5 male) showed the following disease: testis (2), sacrococcygeal (3), ovary (3), retroperitoneum (3), mediastinum (2), and foot soft tissue (1). Distribution of the somatic component was: carcinoma (4), pancreatic neuroendocrine tumor (1), neuroblastoma (3), rhabdomyosarcoma (3), rhabdomyosarcoma plus liposarcoma, chondrosarcoma, neurogenic sarcoma (1), chondro…

Malepediatric patientsAdolescentTeratoma; pediatric patientsSettore MED/20 - Chirurgia Pediatrica E InfantileInfant NewbornTeratomaInfantgerm cell tumorPrognosisSettore MED/38 - Pediatria Generale E SpecialisticaTreatment OutcomeItalyChild PreschoolSettore MED/20Humansmalignant trasformationFemaleChildchildhoodNeoplasm StagingRetrospective Studies
researchProduct

Acute rheumatic fever prophylaxis in high-income countries: clinical observations from an Italian multicentre, retrospective study.

2019

Objective-The aim of the study is to evaluate the compliance rate to secondary prophylaxis and the presence of Rheumatic Heart Disease (RHD) in a cohort of Italian patients with Acute Rheumatic Fever (ARF). Methods-This is a multicentre retrospective study. Patients were divided into two groups according to the presence or absence at last follow-up of RHD. Clinical features, ARF recurrences and the rate of compliance to secondary prophylaxis were evaluated. Results-wo hundred and ninety patients were enrolled (137 females, 153 males). Carditis at onset was present in 244 patients (84.7%). At the end of follow-up, 173 patients showed RHD. Adherence to secondary prophylaxis was low in 26% of …

MaleprophylaxiDeveloped CountriesRheumatic Heart Diseaseacute rheumatic fever; prophylaxis; rheumatic heart diseaseCarditirheumatic heart diseaseAcute rheumatic feveracute rheumatic feverSettore MED/38 - Pediatria Generale E SpecialisticaItalyHumansFemaleprophylaxisProphylaxiRheumatic FeverAcute rheumatic fever Carditis Compliance Prophylaxis Rheumatic heart diseaseComplianceRetrospective StudiesClinical and experimental rheumatology
researchProduct